The significance of bowel permeability

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 10, Issue 5, 2007, Pages 632-638

  Soeters, Peter B ^a,b   Luyer, Misha D ^a   Greve, Jan Willem M ^a   Buurman, Wim A ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bile acids; Inflammation; Intestine; Liver diseases; Malnutrition; Multiple organ failure; Permeability

Indexed keywords

CELIAC DISEASE; DISEASE PREDISPOSITION; DISEASE SEVERITY; EXTRAHEPATIC BILE DUCT OBSTRUCTION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TRACT; HUMAN; INFLAMMATION; INTESTINE; INTESTINE MUCOSA PERMEABILITY; JEJUNOILEAL BYPASS; LIVER; LIVER DISEASE; LIVER FUNCTION TEST; MALNUTRITION; MULTIPLE ORGAN FAILURE; NONHUMAN; OBESITY; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; SEPSIS; SHORT BOWEL SYNDROME; STARVATION;

HUMANS; INFLAMMATION; INTESTINAL DISEASES; INTESTINES; LIVER DISEASES; MALNUTRITION; MULTIPLE ORGAN FAILURE; PERMEABILITY; PROGNOSIS; RISK ASSESSMENT;

EID: 34547854411     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/MCO.0b013e3282a0780e     Document Type: Review

References (50)

1. Travis S, Menzies I. Intestinal permeability: functional assessment and significance. Clin Sci (Lond) 1992; 82:471-488.
2. Marshall JC, Christou NV, Meakins JL. The gastrointestinal tract. The 'undrained abscess' of multiple organ failure. Ann Surg 1993; 218:111-119.
3. Carrico CJ, Meakins JL, Marshall JC, et al. Multiple-organ-failure syndrome. Arch Surg 1986; 121:196-208.
4. Baker JW, Deitch EA, Li M, et al. Hemorrhagic shock induces bacterial translocation from the gut. J Trauma 1988; 28:896-906.
5. Deitch EA, Bridges W, Baker J, et al. Hemorrhagic shock-induced bacterial translocation is reduced by xanthine oxidase inhibition or inactivation. Surgery 1988; 104:191-198.
6. Sori AJ, Rush BF, Lysz TW, et al. The gut as source of sepsis after hemorrhagic shock. Am J Surg 1988; 155:187-192.
7. Riedemann NC, Guo RF, Ward PA. The enigma of sepsis. J Clin Invest 2003; 112:460-467.
8. Fink MP, Delude RL. Epithelial barrier dysfunction: a unifying theme to explain the pathogenesis of multiple organ dysfunction at the cellular level. Crit Care Clin 2005; 21:177-196.
9. Grotz MR, Deitch EA, Ding J, et al. Intestinal cytokine response after gut ischemia: role of gut barrier failure. Ann Surg 1999; 229:478-486.
10. Wyatt J, Vogelsang H, Hübl W, et al. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 1993; 341:1437-1439.
11. Jørgenson J, Ranløv PJ, Bjerrum PJ, et al. Is an increased intestinal permeability a valid predictor of relapse in Crohn disease? Scand J Gastroenterol 2001; 36:521-527.
12. Duerksen DR, Wilhelm-Boyles C, Parry DM. Intestinal permeability in long-term follow-up of patients with celiac disease on a gluten-free diet. Dig Dis Sci 2005; 50:785-790.
13. Harris CE, Griffiths RD, Freestone N, et al. Intestinal permeability in the critically ill. Intensive Care Med 1992; 18:38-41.
14. Lunn PG, Northrop-Clewes CA, Downes RM. Intestinal permeability, mucosal injury, and growth faltering in Gambian infants. Lancet 1991; 338:907-910.
15. Campbell DI, Lunn PG, Elia M. Age-related association of small intestinal mucosal enteropathy with nutritional status in rural Gambian children. Br J Nutr 2002; 88:499-505.
16. Dagci H, Estun S, Taner MS, et al. Protozoon infections and intestinal permeability. Acta Tropica 2002; 81:1-5.
17. Rocha F, Laughlin R, Musch MW, et al. Surgical stress shifts the intestinal Escherichia coli population to that of a more adherent phenotype: role in barrier regulation. Surgery 2001; 130:65-73.
18. Hulsewe KW, van der Hulst RW, van Acker BA, et al. Inflammation rather than nutritional depletion determines glutamine concentrations and intestinal permeability. Clin Nutr 2004; 23:1209-1216.
19. van der Hulst RR, van Kreel BK, von Meyenfeldt MF, et al. Glutamine and the preservation of gut integrity. Lancet 1993; 341:1363-1365.
20. Sedman PC, Macfie J, Sagar P, et al. The prevalence of gut translocation in humans. Gastroenterology 1994; 107:643-649.
21. Welsh FK, Farmery SM, MacLennan K, et al. Gut barrier function in malnourished patients. Gut 1998; 42:396-401.
22. Cavaillon JM, Adib-Conquy M, Fitting C, et al. Cytokine cascade in sepsis. Scand J Infect Dis 2003; 35:535-544.
23. Decker T. Sepsis: avoiding its deadly toll. J Clin Invest 2004; 113:1387-1389.
24. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 2004; 430:257-263.
25. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282:2085-2088.
26. Rinsema W, Gouma DJ, von Meyenfeldt MF, Soeters PB. Reinfusion of secretions from high-output proximal stomas or fistulas. Surg Gynecol Obstet 1988; 167:372-376.
27. Alverdy J, Chi HS, Sheldon GF. The effect of parenteral nutrition on gastrointestinal immunity. The importance of enteral stimulation. Ann Surg 1985; 202:681-684.
28. Spitz JC, Ghandi S, Taveras M, et al. Characteristics of the intestinal epithelial barrier during dietary manipulation and glucocorticoid stress. Crit Care Med 1996; 24:635-641.
29. Alverdy JC, Aoys E. The effect of dexamethasone and endotoxin administration on biliary IgA and bacterial adherence. J Surg Res 1992; 53:450-454.
30. Hofmann AF. Biliary secretion and excretion in health and disease: current concepts. Ann Hepatol 2007; 6:15-27. The importance of normal composition and size of the bile acid pool is highlighted. Biliary synthesis and transport is reviewed and the mechanisms preventing bile acid toxicity. The role of ursodeoxycholic acid is emphasized in normalizing the bile acid pool and diluting toxic bile acids.
31. Hofmann AF. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 1999; 159:2647-2658.
32. Capron JP, Gineston JL, Herve MA, Braillon A. Metronidazole in prevention of cholestasis associated with total parenteral nutrition. Lancet 1983; 1:446-447.
33. Luyer MD, Greve JW, Hadfoune M, et al. Nutritional stimulation of cholecystokinin receptors inhibits inflammation via the vagus nerve. J Exp Med 2005; 202:1023-1029.
34. Kelly DA. Intestinal failure-associated liver disease: what do we know today? Gastroenterology 2006; 130 (2 Suppl 1):S70-S77.
35. Kaufman SS. Prevention of parenteral nutrition-associated liver disease in children. Pediatr Transplant 2002; 6:37-42.
36. Colomb V, Jobert-Giraud A, Lacaille F, et al. Role of lipid emulsions in cholestasis associated with long-term parenteral nutrition in children. JPEN J Parenter Enteral Nutr 2000; 24:345-350.
37. Li J, Stahlgren LH. Glutamine prevents the biliary lithogenic effect of total parenteral nutrition in rats. J Surg Res 1995; 58:491-495.
38. Burke GW 3rd, Cirocco R, Hensley G, et al. Liver transplantation for cirrhosis following jejuno-ileal bypass - regional cytokine differences associated with pathological changes in the transplant liver. Transplantation 1992; 54:374-377.
39. Lowell JA, Shenoy S, Ghalib R, et al. Liver transplantation after jejunoileal bypass for morbid obesity. J Am Coll Surg 1997; 185:123-127.
40. Drenick EJ, Fisler J, Johnson D. Hepatic steatosis after intestinal bypass - prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition. Gastroenterology 1982; 82:535-548.
41. Bondar GF, Pisesky W. Complications of small intestinal short-circuiting for obesity. Arch Surg 1967; 94:707-716.
42. Grant AJ, Lalor PF, Salmi M, et al. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 2002; 359:150-157.
43. Bjornsson E, Cederborg A, Akvist A, et al. Intestinal permeability and bacterial growth of the small bowel in patients with primary sclerosing cholangitis. Scand J Gastroenterol 2005; 40:1090-1094.
44. Farkkila M, Karvonen AL, Nurmi H, et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 2004; 40:1379-1386.
45. Ludvigsson JF, Elfstrom P, Broome U, et al. Celiac disease and risk of liver disease: a general population-based study. Clin Gastroenterol Hepatol 2007; 5:63-69; e1. This study shows that patients with celiac disease are at increased risk for developing or having liver disease.
46. Lawson A, West J, Aithal GP, Logan RF. Autoimmune cholestatic liver disease in people with coeliac disease: a population-based study of their association. Aliment Pharmacol Ther 2005; 21:401-405.
47. Stevens FM, McLoughlin RM. Is coeliac disease a potentially treatable cause of liver failure? Eur J Gastroenterol Hepatol 2005; 17:1015-1017.
48. MacFaul GR, Chapman RW. Sclerosing cholangitis. Curr Opin Gastroenterol 2006; 22:288-293.
49. Koulentaki M, Koutroubakis IE, Petinaki E, et al. Ulcerative colitis associated with primary biliary cirrhosis. Dig Dis Sci 1999; 44:1953-1956.
50. Howell WM, Calder PC, Grimble RF. Gene polymorphisms, inflammatory diseases and cancer. Proc Nutr Soc 2002; 61:447-456.